Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevent CINC-J: High-dose pitavastatin to prevent contrast-induced nephropathy
jRCTs051180189Completed
- Sponsor
- Abbott Laboratories
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of pitavastatin in contrast-induced nephropathy (CIN) (2 arms), sponsored by Abbott Laboratories. Primary endpoints: Contrast-induced nephropathy incidence and Main safety evaluations. Started Jul 2016; status: completed.
02
Drugs
pitavastatin
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on jRCTs051180189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180189.